The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
As of Oct 20, 2026
During the third quarter of 2026, the Driehaus Micro Cap Growth Strategy declined 14.25% net of fees, underperforming its benchmark, the Russell Microcap Growth Index, which fell 12.15%. Year-to-date, the strategy has generated a net return of 15.27% net of fees, outpacing the benchmark's 8.50% gain by 677 basis points. For broader context, the Russell Microcap Index fell 7.20%, the Russell 2000 Index declined 7.23%, and the S&P 500 gained 2.3%. Cash ended the period at a modest 1.9%, reflecting a largely fully invested posture across 124 holdings with an active share of 79.09%. Macroeconomic headwinds were dominated by surging 10-year and 30-year Treasury yields eclipsing 5%, driven by resilient nominal GDP, massive hyperscaler capital expenditure, persistent inflation above target, fiscal deficit expansion, and the unwind of the Japanese yen carry trade. This rate shock prompted severe valuation multiple compression across high-momentum small-cap growth equities. Meanwhile, artificial intelligence and data center infrastructure names suffered a sharp factor unwind in July and August amid concerns over data center permitting, circular financing, and model economics, which the manager views as transient noise relative to durable compute demand. Portfolio activity centered on aggressive factor and sector rebalancing. The strategy meaningfully trimmed its overweight in industrials—reducing engineering, electrical equipment, and aerospace suppliers to a slight underweight—and reduced semiconductor and hardware exposure following significant outperformance. Proceeds were reallocated toward agentic software and cybersecurity holdings, as well as selected commercial-stage biotechnology and diagnostics opportunities. Key disclosed portfolio holdings include Praxis Precision Medicines, Spyre Therapeutics, Bandwidth, and Amylyx Pharmaceuticals.
The strategy seeks superior capital appreciation by opportunistically investing in micro-cap growth companies demonstrating robust earnings revisions, accelerating fundamental momentum, and durable secular expansion.
Management remains constructive on the near-term market outlook as resilient US economic growth, corporate earnings progression, and attractive small-cap valuations offset interest rate volatility.
Neutral / Balanced
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon
Top Conviction Themes
Key Catalysts
Every insight in this database connects to the original source. Read the actual thesis, see the actual concerns, and make your own call.
Buyside Digest has no business relationship, partnership, agency, sponsorship, endorsement, or affiliation with Driehaus Micro Cap Growth Strategy or any other manager whose content appears on the Service, except where expressly stated. We do not receive Manager Content directly from managers in most cases; content is collected from publicly available sources. Managers have not necessarily reviewed, approved, authorized, or endorsed our display of their content, our editorial commentary, our metadata extraction, or our classifications. Use of a manager’s name is for accurate attribution and identification purposes only, under principles of nominative fair use.
Buyside Digest does not independently verify the regulatory status, registrations, licensing, qualifications, credentials, or professional standing of managers whose content appears on the Service. We do not represent that managers are properly registered with applicable regulatory bodies, that their content complies with applicable securities laws, or that their performance representations are accurate. Inclusion of a manager in our database is based on the publicly available nature of their content, not on our verification of their regulatory status or content compliance. Users are responsible for conducting their own due diligence on any manager.
Performance data, returns, assets under management (“AUM”), and similar figures displayed on this page are sourced from publicly available manager communications (including investor letters), public filings, or other third-party sources. Buyside Digest does not independently verify performance figures, calculate returns, or audit manager-reported data. Such figures: May be selectively reported by the manager; May use non-standard calculation methodologies; May not reflect fees, expenses, taxes, or other costs; May be inconsistent across reporting periods; May be outdated. Past performance is not indicative of future results. Performance figures should not be relied upon for investment decisions without independent verification. Users should request audited performance data directly from the manager and conduct their own due diligence.